Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Dr. Richard Finn on the Rationale for Targeting CDK4/6

March 4th 2013

Richard Finn, MD, from Jonsson Comprehensive Cancer Center, discusses the rationale for targeting cyclin-dependent kinases 4 and 6 with the novel agent PD 0332991 in breast cancer.

Dr. Bendell on Hsp90 Inhibition in Advanced Solid Tumors

March 4th 2013

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.

Justin Balko on JAK2 Amplification in TNBC

February 28th 2013

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, describes a study that discovered JAK2 alterations in patients with treatment-refractory triple-negative breast cancer.

Dr. Vahdat on Frontline Eribulin Plus Trastuzumab in MBC

February 26th 2013

Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.

T-DM1 Approved for HER2-Positive Metastatic Breast Cancer

February 22nd 2013

The FDA has approved ado-trastuzumab emtansine, also known as T-DM1, for HER2-positive metastatic breast cancer.

Alterations in CYP2D6 Enzyme Affect Efficacy of Tamoxifen

February 21st 2013

Genetic or drug-induced alterations of the enzyme CYP2D6 that result in reduced metabolism of tamoxifen are associated with a higher risk of recurrence and death in women with ER–positive breast cancer who receive the drug.

Dr. Twelves Highlights Findings From the 2012 SABCS

February 21st 2013

Christopher Twelves, MD, Professor and Honorary Consultant in Medical Oncology, University of Leeds, highlights key findings from the 2012 San Antonio Breast Cancer Symposium, which took place in December 2012.

Dr. Gradishar on Enriching Targeted Therapy Trials

February 19th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes the need to enrich the patient population in a clinical trial that is investigating a novel targeted therapy.

Dr. Perez on the Antibody-Drug Conjugate T-DM1

February 13th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, discusses the antibody-drug conjugate T-DM1 that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Dr. Tripathy on 10 Versus 5 Years of Adjuvant Tamoxifen

February 12th 2013

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the ATLAS trial that compared 5 years of adjuvant tamoxifen to 10 in patients with estrogen receptor-positive early breast cancer.

A Journey of a Lifetime: Noted Breast Cancer Researcher in Far-Flung Pursuit of a "Cure"

February 12th 2013

Leyland-Jones, MB BS, PhD, a renowned oncologist and translational scientist, has helped develop several mainstay oncologic treatments and the targeted breast cancer therapy trastuzumab.

Dr. William Gradishar Reviews the Eribulin 301 Study

February 8th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes results from the 301 Study that compared eribulin mesylate to capecitabine for locally advanced or metastatic breast cancer.

Dr. Kaufman on Eribulin/ Capecitabine Side Effects

February 7th 2013

Peter A. Kaufman, MD, Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth, discusses the side effect profiles of the microtubule inhibitor eribulin mesylate and the oral chemotherapeutic agent capecitabine.

SABCS Report: Tackling the Optimal Use of Established Therapies

February 6th 2013

In interviews with OncologyLive, Debu Tripathy, MD, and William Gradishar, MD, discussed their views of the most important abstracts presented during the San Antonio Breast Cancer Symposium.

Dr. Mamounas on Surgery in Stage IV Breast Cancer

February 6th 2013

Eleftherios (Terry) P. Mamounas, MD, MPH, from the Aultman Hospital Cancer Center, discusses the controversial topic of surgery for patients who present with stage IV breast cancer at the time of diagnosis.

HER2 Mutations Identified as Treatment Targets in Patients With HER2-Negative Breast Cancer

February 5th 2013

Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.

Dr. Debu Tripathy Reviews the Phase III CONFIRM Trial

February 4th 2013

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the final analysis of overall survival for the phase III CONFIRM trial.

Expert Analysis From SABCS 2012: An Interview With Edith Perez, MD

February 1st 2013

Discussion with Edith Perez, MD, about key research presented at SABCS, ongoing developments in breast cancer treatment, and the current focal areas of her research.

Guideline Adherence Is Vital to HER2 Accuracy

January 31st 2013

Efforts to improve guidelines continue for HER2 testing and the evaluation of whether patients' tumors are estrogen receptor-positive and progesterone receptor-positive.

Breast-Conserving Treatment of Breast Cancer

January 29th 2013

An effective alternative to mastectomy for early stage disease regardless of age or hormone receptor status.

NEXT PAGE
PREVIOUS PAGE